| Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. | |
| | |
MedLine Citation:
|
PMID: 22252465 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines recommend alemtuzumab subcutaneous (SC) over IV. There is no report of alemtuzumab SC in MS. We report two patients with highly active relapsing MS who were treated with SC alemtuzumab, had significant improvement and tolerated SC alemtuzumab well without the typical infusion-associated adverse events. SC alemtuzumab in MS warrants further studies as this may enhance patient convenience and minimize infusion-associated adverse events. |
| | |
Authors:
|
Jai S Perumal; Farng Foo; Perry Cook; Omar Khan |
Related Documents
:
|
11840105 - Adult scoliosis: a quantitative radiographic and clinical analysis. 19548935 - The prevalence of anterior teeth with dens invaginatus in the western mediterranean reg... 21119115 - Clinical similarities and differences of patients with x-linked lymphoproliferative syn... 490525 - Radiological manifestations in 200 patients with ankylosing spondylitis: correlation wi... 11860615 - Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines. 12843685 - Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and re... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-17 |
Journal Detail:
|
Title: Multiple sclerosis (Houndmills, Basingstoke, England) Volume: - ISSN: 1477-0970 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9509185 Medline TA: Mult Scler Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Neurology, Weill Cornell Medical College, New York, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The oncology of otology.
Next Document: No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients.